date:Mar 28, 2013
bout $12.4 billion in China since 2002 as mothers in an ever-expanding workforce spend less time breastfeeding.
A safe, foreign material-based, manufactured infant formula demands a staggering premium in the Chinese market, said David Mahon, managing director of Mahon China Investment Management in Beijing, which advises Chinese and New Zealand firms.
That's where the profit margins are.
Fonterra CEO Theo Spierings said he planned to expand the company's offerings of its Anmum maternal formul